nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—ADRA1A—polycystic ovary syndrome	0.753	1	CbGaD
Escitalopram—Seasonal allergy—Metformin—polycystic ovary syndrome	0.00703	0.0583	CcSEcCtD
Escitalopram—Rhinitis seasonal—Metformin—polycystic ovary syndrome	0.00674	0.0559	CcSEcCtD
Escitalopram—Citalopram—ADRA1A—polycystic ovary syndrome	0.00596	1	CrCbGaD
Escitalopram—Tonsillitis—Metformin—polycystic ovary syndrome	0.00583	0.0483	CcSEcCtD
Escitalopram—Taste metallic—Metformin—polycystic ovary syndrome	0.00463	0.0384	CcSEcCtD
Escitalopram—Sinus headache—Metformin—polycystic ovary syndrome	0.00452	0.0375	CcSEcCtD
Escitalopram—Tooth abscess—Metformin—polycystic ovary syndrome	0.00353	0.0292	CcSEcCtD
Escitalopram—Emotional distress—Metformin—polycystic ovary syndrome	0.00346	0.0287	CcSEcCtD
Escitalopram—Abdominal bloating—Metformin—polycystic ovary syndrome	0.00309	0.0256	CcSEcCtD
Escitalopram—Sinus congestion—Metformin—polycystic ovary syndrome	0.00296	0.0245	CcSEcCtD
Escitalopram—Epigastric discomfort—Metformin—polycystic ovary syndrome	0.0028	0.0232	CcSEcCtD
Escitalopram—Toothache—Metformin—polycystic ovary syndrome	0.00242	0.0201	CcSEcCtD
Escitalopram—Upset stomach—Metformin—polycystic ovary syndrome	0.00225	0.0186	CcSEcCtD
Escitalopram—Heartburn—Metformin—polycystic ovary syndrome	0.00214	0.0177	CcSEcCtD
Escitalopram—Fungal infection—Metformin—polycystic ovary syndrome	0.00191	0.0158	CcSEcCtD
Escitalopram—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.00182	0.0151	CcSEcCtD
Escitalopram—Rigors—Metformin—polycystic ovary syndrome	0.0018	0.015	CcSEcCtD
Escitalopram—Contusion—Metformin—polycystic ovary syndrome	0.00169	0.014	CcSEcCtD
Escitalopram—Chest discomfort—Metformin—polycystic ovary syndrome	0.00166	0.0138	CcSEcCtD
Escitalopram—Accidental injury—Metformin—polycystic ovary syndrome	0.00166	0.0138	CcSEcCtD
Escitalopram—Neuropathy—Metformin—polycystic ovary syndrome	0.00138	0.0115	CcSEcCtD
Escitalopram—Lightheadedness—Metformin—polycystic ovary syndrome	0.00132	0.0109	CcSEcCtD
Escitalopram—Ear pain—Metformin—polycystic ovary syndrome	0.00125	0.0104	CcSEcCtD
Escitalopram—Nasal congestion—Metformin—polycystic ovary syndrome	0.00117	0.00973	CcSEcCtD
Escitalopram—Injury—Metformin—polycystic ovary syndrome	0.00116	0.00964	CcSEcCtD
Escitalopram—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.0011	0.00908	CcSEcCtD
Escitalopram—Lethargy—Metformin—polycystic ovary syndrome	0.00109	0.00904	CcSEcCtD
Escitalopram—Pain in extremity—Metformin—polycystic ovary syndrome	0.00107	0.00886	CcSEcCtD
Escitalopram—Migraine—Metformin—polycystic ovary syndrome	0.00105	0.00872	CcSEcCtD
Escitalopram—Dehydration—Metformin—polycystic ovary syndrome	0.000994	0.00824	CcSEcCtD
Escitalopram—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.000987	0.00818	CcSEcCtD
Escitalopram—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.000976	0.00809	CcSEcCtD
Escitalopram—Breast disorder—Metformin—polycystic ovary syndrome	0.000966	0.00801	CcSEcCtD
Escitalopram—Cramp muscle—Metformin—polycystic ovary syndrome	0.000963	0.00798	CcSEcCtD
Escitalopram—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.000956	0.00792	CcSEcCtD
Escitalopram—Abdominal distension—Metformin—polycystic ovary syndrome	0.00093	0.00771	CcSEcCtD
Escitalopram—Influenza—Metformin—polycystic ovary syndrome	0.000924	0.00766	CcSEcCtD
Escitalopram—Pancreatitis—Metformin—polycystic ovary syndrome	0.000906	0.00751	CcSEcCtD
Escitalopram—Sweating increased—Metformin—polycystic ovary syndrome	0.0009	0.00746	CcSEcCtD
Escitalopram—Angina pectoris—Metformin—polycystic ovary syndrome	0.0009	0.00746	CcSEcCtD
Escitalopram—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000886	0.00734	CcSEcCtD
Escitalopram—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000859	0.00712	CcSEcCtD
Escitalopram—Infestation—Metformin—polycystic ovary syndrome	0.000824	0.00683	CcSEcCtD
Escitalopram—Infestation NOS—Metformin—polycystic ovary syndrome	0.000824	0.00683	CcSEcCtD
Escitalopram—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.000808	0.00669	CcSEcCtD
Escitalopram—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000779	0.00646	CcSEcCtD
Escitalopram—Bradycardia—Metformin—polycystic ovary syndrome	0.000753	0.00624	CcSEcCtD
Escitalopram—Rhinitis—Metformin—polycystic ovary syndrome	0.000741	0.00615	CcSEcCtD
Escitalopram—Hepatitis—Metformin—polycystic ovary syndrome	0.00074	0.00613	CcSEcCtD
Escitalopram—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000736	0.0061	CcSEcCtD
Escitalopram—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000729	0.00604	CcSEcCtD
Escitalopram—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000727	0.00602	CcSEcCtD
Escitalopram—Eye disorder—Metformin—polycystic ovary syndrome	0.000691	0.00573	CcSEcCtD
Escitalopram—Flushing—Metformin—polycystic ovary syndrome	0.000686	0.00569	CcSEcCtD
Escitalopram—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000686	0.00569	CcSEcCtD
Escitalopram—Angiopathy—Metformin—polycystic ovary syndrome	0.000671	0.00556	CcSEcCtD
Escitalopram—Immune system disorder—Metformin—polycystic ovary syndrome	0.000668	0.00554	CcSEcCtD
Escitalopram—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000666	0.00552	CcSEcCtD
Escitalopram—Chills—Metformin—polycystic ovary syndrome	0.000664	0.0055	CcSEcCtD
Escitalopram—Malnutrition—Metformin—polycystic ovary syndrome	0.000644	0.00534	CcSEcCtD
Escitalopram—Erythema—Metformin—polycystic ovary syndrome	0.000644	0.00534	CcSEcCtD
Escitalopram—Flatulence—Metformin—polycystic ovary syndrome	0.000634	0.00526	CcSEcCtD
Escitalopram—Dysgeusia—Metformin—polycystic ovary syndrome	0.00063	0.00523	CcSEcCtD
Escitalopram—Muscle spasms—Metformin—polycystic ovary syndrome	0.000619	0.00513	CcSEcCtD
Escitalopram—Vision blurred—Metformin—polycystic ovary syndrome	0.000607	0.00503	CcSEcCtD
Escitalopram—Tremor—Metformin—polycystic ovary syndrome	0.000603	0.005	CcSEcCtD
Escitalopram—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000597	0.00495	CcSEcCtD
Escitalopram—Malaise—Metformin—polycystic ovary syndrome	0.000581	0.00481	CcSEcCtD
Escitalopram—Syncope—Metformin—polycystic ovary syndrome	0.000577	0.00479	CcSEcCtD
Escitalopram—Palpitations—Metformin—polycystic ovary syndrome	0.000569	0.00472	CcSEcCtD
Escitalopram—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000566	0.00469	CcSEcCtD
Escitalopram—Hypertension—Metformin—polycystic ovary syndrome	0.000556	0.00461	CcSEcCtD
Escitalopram—Chest pain—Metformin—polycystic ovary syndrome	0.000548	0.00454	CcSEcCtD
Escitalopram—Myalgia—Metformin—polycystic ovary syndrome	0.000548	0.00454	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000544	0.00451	CcSEcCtD
Escitalopram—Discomfort—Metformin—polycystic ovary syndrome	0.000542	0.00449	CcSEcCtD
Escitalopram—Oedema—Metformin—polycystic ovary syndrome	0.000525	0.00436	CcSEcCtD
Escitalopram—Infection—Metformin—polycystic ovary syndrome	0.000522	0.00433	CcSEcCtD
Escitalopram—Shock—Metformin—polycystic ovary syndrome	0.000517	0.00428	CcSEcCtD
Escitalopram—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000515	0.00427	CcSEcCtD
Escitalopram—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000514	0.00426	CcSEcCtD
Escitalopram—Skin disorder—Metformin—polycystic ovary syndrome	0.00051	0.00423	CcSEcCtD
Escitalopram—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000508	0.00421	CcSEcCtD
Escitalopram—Anorexia—Metformin—polycystic ovary syndrome	0.000501	0.00415	CcSEcCtD
Escitalopram—Hypotension—Metformin—polycystic ovary syndrome	0.000491	0.00407	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000479	0.00397	CcSEcCtD
Escitalopram—Paraesthesia—Metformin—polycystic ovary syndrome	0.000472	0.00391	CcSEcCtD
Escitalopram—Dyspnoea—Metformin—polycystic ovary syndrome	0.000468	0.00388	CcSEcCtD
Escitalopram—Somnolence—Metformin—polycystic ovary syndrome	0.000467	0.00387	CcSEcCtD
Escitalopram—Dyspepsia—Metformin—polycystic ovary syndrome	0.000462	0.00383	CcSEcCtD
Escitalopram—Decreased appetite—Metformin—polycystic ovary syndrome	0.000457	0.00379	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000454	0.00376	CcSEcCtD
Escitalopram—Fatigue—Metformin—polycystic ovary syndrome	0.000453	0.00375	CcSEcCtD
Escitalopram—Constipation—Metformin—polycystic ovary syndrome	0.000449	0.00372	CcSEcCtD
Escitalopram—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000433	0.00359	CcSEcCtD
Escitalopram—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00043	0.00356	CcSEcCtD
Escitalopram—Urticaria—Metformin—polycystic ovary syndrome	0.000417	0.00346	CcSEcCtD
Escitalopram—Abdominal pain—Metformin—polycystic ovary syndrome	0.000415	0.00344	CcSEcCtD
Escitalopram—Asthenia—Metformin—polycystic ovary syndrome	0.000377	0.00312	CcSEcCtD
Escitalopram—Pruritus—Metformin—polycystic ovary syndrome	0.000372	0.00308	CcSEcCtD
Escitalopram—Diarrhoea—Metformin—polycystic ovary syndrome	0.000359	0.00298	CcSEcCtD
Escitalopram—Dizziness—Metformin—polycystic ovary syndrome	0.000347	0.00288	CcSEcCtD
Escitalopram—Vomiting—Metformin—polycystic ovary syndrome	0.000334	0.00277	CcSEcCtD
Escitalopram—Rash—Metformin—polycystic ovary syndrome	0.000331	0.00275	CcSEcCtD
Escitalopram—Dermatitis—Metformin—polycystic ovary syndrome	0.000331	0.00274	CcSEcCtD
Escitalopram—Headache—Metformin—polycystic ovary syndrome	0.000329	0.00273	CcSEcCtD
Escitalopram—Nausea—Metformin—polycystic ovary syndrome	0.000312	0.00259	CcSEcCtD
Escitalopram—CYP2D6—Metabolism—PNPLA2—polycystic ovary syndrome	2.58e-05	0.000215	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.57e-05	0.000214	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.57e-05	0.000214	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—FST—polycystic ovary syndrome	2.56e-05	0.000213	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RBP4—polycystic ovary syndrome	2.56e-05	0.000213	CbGpPWpGaD
Escitalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	2.55e-05	0.000212	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—LPCAT2—polycystic ovary syndrome	2.54e-05	0.000212	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SUOX—polycystic ovary syndrome	2.54e-05	0.000212	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—LHB—polycystic ovary syndrome	2.54e-05	0.000212	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	2.54e-05	0.000212	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—LHB—polycystic ovary syndrome	2.53e-05	0.000211	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—STAR—polycystic ovary syndrome	2.53e-05	0.000211	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.53e-05	0.00021	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.52e-05	0.00021	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	2.5e-05	0.000209	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—LHB—polycystic ovary syndrome	2.5e-05	0.000208	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.49e-05	0.000207	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.48e-05	0.000206	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SRD5A1—polycystic ovary syndrome	2.44e-05	0.000203	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.44e-05	0.000203	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.41e-05	0.0002	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.4e-05	0.0002	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.4e-05	0.0002	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.39e-05	0.000199	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—YAP1—polycystic ovary syndrome	2.39e-05	0.000199	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SCT—polycystic ovary syndrome	2.38e-05	0.000198	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SCT—polycystic ovary syndrome	2.38e-05	0.000198	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ISYNA1—polycystic ovary syndrome	2.36e-05	0.000197	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.36e-05	0.000197	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.36e-05	0.000196	CbGpPWpGaD
Escitalopram—CYP3A4—Biological oxidations—POMC—polycystic ovary syndrome	2.36e-05	0.000196	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GAB1—polycystic ovary syndrome	2.35e-05	0.000196	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.35e-05	0.000196	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.34e-05	0.000195	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SCT—polycystic ovary syndrome	2.34e-05	0.000195	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—STAR—polycystic ovary syndrome	2.33e-05	0.000194	CbGpPWpGaD
Escitalopram—CHRM1—Circadian rythm related genes—IL6—polycystic ovary syndrome	2.32e-05	0.000193	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.31e-05	0.000192	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.27e-05	0.000189	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.27e-05	0.000189	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—HMMR—polycystic ovary syndrome	2.26e-05	0.000188	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—INSR—polycystic ovary syndrome	2.25e-05	0.000187	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—FGF18—polycystic ovary syndrome	2.23e-05	0.000186	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.23e-05	0.000186	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—FGF18—polycystic ovary syndrome	2.23e-05	0.000185	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RBP4—polycystic ovary syndrome	2.22e-05	0.000184	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RBP4—polycystic ovary syndrome	2.21e-05	0.000184	CbGpPWpGaD
Escitalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	2.21e-05	0.000184	CbGpPWpGaD
Escitalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	2.2e-05	0.000183	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—FGF18—polycystic ovary syndrome	2.19e-05	0.000183	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.18e-05	0.000182	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.17e-05	0.000181	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RBP4—polycystic ovary syndrome	2.17e-05	0.000181	CbGpPWpGaD
Escitalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	2.16e-05	0.00018	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—HSD3B1—polycystic ovary syndrome	2.15e-05	0.000179	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.14e-05	0.000178	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.14e-05	0.000178	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	2.13e-05	0.000177	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.11e-05	0.000175	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PGR—polycystic ovary syndrome	2.08e-05	0.000174	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	2.08e-05	0.000173	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—YAP1—polycystic ovary syndrome	2.07e-05	0.000172	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—YAP1—polycystic ovary syndrome	2.06e-05	0.000172	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GAB1—polycystic ovary syndrome	2.04e-05	0.00017	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GAB1—polycystic ovary syndrome	2.03e-05	0.000169	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—YAP1—polycystic ovary syndrome	2.03e-05	0.000169	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	2.02e-05	0.000168	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	2.01e-05	0.000167	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	2.01e-05	0.000167	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GAB1—polycystic ovary syndrome	2e-05	0.000167	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	1.98e-05	0.000165	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—LHB—polycystic ovary syndrome	1.96e-05	0.000164	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—INSR—polycystic ovary syndrome	1.95e-05	0.000162	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—INSR—polycystic ovary syndrome	1.94e-05	0.000162	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PLAT—polycystic ovary syndrome	1.94e-05	0.000161	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GHRL—polycystic ovary syndrome	1.94e-05	0.000161	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—HSD3B2—polycystic ovary syndrome	1.92e-05	0.00016	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—INSR—polycystic ovary syndrome	1.91e-05	0.000159	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.87e-05	0.000155	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AKR1C1—polycystic ovary syndrome	1.86e-05	0.000155	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.85e-05	0.000154	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ATF1—polycystic ovary syndrome	1.85e-05	0.000154	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.85e-05	0.000154	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.82e-05	0.000152	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.82e-05	0.000151	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.82e-05	0.000151	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	1.81e-05	0.00015	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PGR—polycystic ovary syndrome	1.81e-05	0.00015	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.8e-05	0.00015	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PGR—polycystic ovary syndrome	1.8e-05	0.00015	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.79e-05	0.000149	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.79e-05	0.000149	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PGR—polycystic ovary syndrome	1.77e-05	0.000148	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	1.77e-05	0.000147	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	1.71e-05	0.000142	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	1.71e-05	0.000142	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NGFR—polycystic ovary syndrome	1.71e-05	0.000142	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—POMC—polycystic ovary syndrome	1.69e-05	0.000141	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PRL—polycystic ovary syndrome	1.69e-05	0.000141	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	1.68e-05	0.00014	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PLAT—polycystic ovary syndrome	1.68e-05	0.00014	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GHRL—polycystic ovary syndrome	1.68e-05	0.00014	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GHRL—polycystic ovary syndrome	1.67e-05	0.000139	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PLAT—polycystic ovary syndrome	1.67e-05	0.000139	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	1.66e-05	0.000138	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.65e-05	0.000137	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.65e-05	0.000137	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.63e-05	0.000136	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.62e-05	0.000135	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.61e-05	0.000134	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.6e-05	0.000134	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ATF1—polycystic ovary syndrome	1.6e-05	0.000133	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	1.6e-05	0.000133	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	1.6e-05	0.000133	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ATF1—polycystic ovary syndrome	1.6e-05	0.000133	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.59e-05	0.000132	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	1.57e-05	0.000131	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ATF1—polycystic ovary syndrome	1.57e-05	0.000131	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.56e-05	0.00013	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.56e-05	0.00013	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.55e-05	0.000129	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.55e-05	0.000129	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	1.53e-05	0.000128	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.53e-05	0.000128	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	1.53e-05	0.000127	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.53e-05	0.000127	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	1.52e-05	0.000127	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	1.52e-05	0.000127	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	1.52e-05	0.000126	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	1.5e-05	0.000125	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—GNAS—polycystic ovary syndrome	1.49e-05	0.000124	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NGFR—polycystic ovary syndrome	1.48e-05	0.000123	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NGFR—polycystic ovary syndrome	1.47e-05	0.000123	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	1.47e-05	0.000122	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—POMC—polycystic ovary syndrome	1.47e-05	0.000122	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PRL—polycystic ovary syndrome	1.46e-05	0.000122	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—POMC—polycystic ovary syndrome	1.46e-05	0.000122	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PRL—polycystic ovary syndrome	1.46e-05	0.000122	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NGFR—polycystic ovary syndrome	1.45e-05	0.000121	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—POMC—polycystic ovary syndrome	1.44e-05	0.00012	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PRL—polycystic ovary syndrome	1.44e-05	0.00012	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	1.43e-05	0.000119	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.42e-05	0.000118	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	1.41e-05	0.000118	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.41e-05	0.000118	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	1.41e-05	0.000117	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.41e-05	0.000117	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	1.39e-05	0.000116	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NRG1—polycystic ovary syndrome	1.39e-05	0.000116	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.39e-05	0.000116	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.39e-05	0.000115	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.39e-05	0.000115	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.36e-05	0.000114	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	1.36e-05	0.000113	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	1.32e-05	0.00011	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	1.3e-05	0.000108	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	1.3e-05	0.000108	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—GNAS—polycystic ovary syndrome	1.29e-05	0.000107	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—GNAS—polycystic ovary syndrome	1.28e-05	0.000107	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.26e-05	0.000105	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.23e-05	0.000102	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.22e-05	0.000102	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—TH—polycystic ovary syndrome	1.22e-05	0.000102	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.2e-05	0.0001	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.2e-05	0.0001	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.2e-05	0.0001	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IRS2—polycystic ovary syndrome	1.19e-05	9.92e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	1.19e-05	9.88e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.18e-05	9.85e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	1.18e-05	9.84e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—LEP—polycystic ovary syndrome	1.17e-05	9.71e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	1.15e-05	9.61e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TH—polycystic ovary syndrome	1.12e-05	9.34e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	1.12e-05	9.31e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	1.12e-05	9.29e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	1.09e-05	9.08e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IRS1—polycystic ovary syndrome	1.04e-05	8.66e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.03e-05	8.59e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	1.03e-05	8.57e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.03e-05	8.57e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	1.03e-05	8.54e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.01e-05	8.43e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	1.01e-05	8.41e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—LEP—polycystic ovary syndrome	1.01e-05	8.38e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—POMC—polycystic ovary syndrome	1e-05	8.34e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	9.97e-06	8.3e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—INS—polycystic ovary syndrome	9.96e-06	8.29e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	9.95e-06	8.29e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	9.91e-06	8.25e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IGF1—polycystic ovary syndrome	9.63e-06	8.02e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AKT2—polycystic ovary syndrome	9.62e-06	8.01e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	9.61e-06	8e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	9.48e-06	7.9e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	9.23e-06	7.69e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	9.16e-06	7.62e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.15e-06	7.62e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	9.12e-06	7.59e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	9.01e-06	7.5e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	8.99e-06	7.49e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IRS1—polycystic ovary syndrome	8.98e-06	7.48e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	8.84e-06	7.36e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	8.72e-06	7.26e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	8.68e-06	7.22e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—POMC—polycystic ovary syndrome	8.65e-06	7.2e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	8.63e-06	7.18e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	8.61e-06	7.17e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—INS—polycystic ovary syndrome	8.6e-06	7.16e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	8.51e-06	7.09e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	8.47e-06	7.06e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	8.47e-06	7.05e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	8.38e-06	6.98e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	8.35e-06	6.95e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	8.34e-06	6.94e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IGF1—polycystic ovary syndrome	8.32e-06	6.93e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKT2—polycystic ovary syndrome	8.31e-06	6.92e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	8.27e-06	6.88e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	8.19e-06	6.82e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	8.18e-06	6.81e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.93e-06	6.6e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.9e-06	6.58e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.78e-06	6.48e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	7.71e-06	6.42e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—IL6—polycystic ovary syndrome	7.37e-06	6.13e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TH—polycystic ovary syndrome	7.33e-06	6.11e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	7.13e-06	5.94e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	6.8e-06	5.66e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	6.71e-06	5.58e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	6.7e-06	5.58e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—INS—polycystic ovary syndrome	6.67e-06	5.55e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	6.38e-06	5.31e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—IL6—polycystic ovary syndrome	6.36e-06	5.3e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.29e-06	5.24e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	6.26e-06	5.21e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	6.25e-06	5.2e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	6.16e-06	5.13e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—INS—polycystic ovary syndrome	6.13e-06	5.1e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	5.99e-06	4.98e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	5.7e-06	4.75e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.45e-06	4.54e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.43e-06	4.52e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	5.41e-06	4.5e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.35e-06	4.45e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	5.04e-06	4.2e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL6—polycystic ovary syndrome	4.35e-06	3.62e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	4.09e-06	3.4e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	4.03e-06	3.36e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—INS—polycystic ovary syndrome	4.01e-06	3.34e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	3.77e-06	3.14e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL6—polycystic ovary syndrome	3.76e-06	3.13e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	3.7e-06	3.08e-05	CbGpPWpGaD
